Goodpasture syndrome is a rare autoimmune disease in which the immune system produces antibodies that attack the kidneys and, in many cases, the lungs. The antibodies target a specific protein in the thin membranes that line the kidney’s filtering units and the lung’s air sacs, triggering inflammation that can rapidly destroy both organs. The condition is now more commonly called anti-glomerular basement membrane (anti-GBM) disease, reflecting the central role those antibodies play in diagnosis and treatment.1PubMed. Diagnosis and classification of Goodpasture’s disease (anti-GBM) Although it accounts for a small fraction of kidney emergencies, its speed and severity make it one of the most urgent diagnoses in nephrology.
What the Immune System Actually Attacks
The target of the rogue antibodies is a single chain of type IV collagen, called the alpha-3 chain, which is a structural building block of basement membranes throughout the body. The antibodies home in on one particular region of that chain known as the NC1 domain.2PubMed. The alpha 3 chain of type IV collagen induces autoimmune Goodpasture syndrome Under normal circumstances the NC1 domain is tucked inside the collagen network, hidden from immune surveillance. When something exposes it, the immune system can mistake it for a foreign invader and begin producing antibodies against it.
These antibodies bind directly along the basement membrane in a smooth, continuous line, a pattern pathologists describe as “linear” staining for immunoglobulin. That linear pattern on a kidney biopsy is one of the hallmarks of the disease.3PubMed. Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques The damage is not just antibody-driven; immune cells also pile in. Research shows that both autoantibodies and cell-mediated immunity contribute to tissue destruction, and in patients who recover, regulatory immune cells appear to help shut down the attack during the convalescent phase.
Who Is at Risk
Anti-GBM disease is rare enough that most nephrologists see only a handful of cases in a career. It has two rough peaks in age: one in young adults (typically men in their twenties and thirties) and another in older adults (often women in their sixties and seventies). The reasons for that bimodal pattern are not fully understood, but genetics plays a measurable role.
The strongest known genetic risk factor is carrying a particular immune-system gene variant called HLA-DRB1*15:01. Studies consistently find a strong association between this allele and susceptibility to the disease.4PubMed Central. The HLA-DRB1*15:01-restricted Goodpasture’s T cell epitope induces GN One large genetic analysis found the odds of developing anti-GBM disease were roughly four to five times higher in carriers of this variant compared with non-carriers.5PubMed Central. The susceptible HLA class II alleles and their presenting epitope(s) in Goodpasture’s disease Interestingly, other HLA variants (DRB1*07:01 and DRB1*01:01) appear to be protective, meaning people who carry them are less likely to develop the disease even if they are exposed to the same environmental insults.
Carrying the susceptibility gene alone is not enough. Most people with HLA-DRB1*15:01 never develop the disease. An environmental trigger usually has to expose the hidden collagen target to the immune system before the process starts.
Environmental Triggers
Cigarette smoking is the most clearly documented trigger for lung involvement. In one landmark study of patients with confirmed anti-GBM disease, all 37 who smoked had lung hemorrhage, compared with only two of ten non-smokers, even though antibody levels in the two groups were similar.6PubMed. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane In one patient, resuming smoking after a period of abstinence promptly brought the bleeding back. Smoking appears to damage the lung’s capillary lining just enough to let the circulating antibodies reach the basement membrane and trigger hemorrhage.
Hydrocarbon exposure is another recognized trigger. Case reports and occupational studies have linked the disease to solvents, degreasers, paint products, jet fuel, and other chemical exposures.7American Journal of Industrial Medicine. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture’s syndrome) Workers exposed to hydrocarbons and mixed solvents have been found to have higher rates of anti-GBM antibodies and signs of basement-membrane damage compared with unexposed controls.8QJM: An International Journal of Medicine. Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents Infections, certain drugs, and other lung injuries have also been proposed as triggers in individual cases, though the evidence for those is less systematic.
Symptoms and Presentation
The classic presentation involves two organ systems simultaneously. In the kidneys, inflammation destroys the tiny filtering units (glomeruli), causing blood and protein to spill into the urine and kidney function to plummet over days to weeks. Many patients arrive at the hospital already in severe kidney failure. In the lungs, the same antibodies attack the capillary walls in the air sacs, producing hemorrhage that can range from mild breathlessness and cough to life-threatening bleeding.
Not everyone gets both. Some patients present with kidney disease alone, without any lung symptoms. Isolated lung hemorrhage without kidney involvement is rarer. The presence or absence of lung bleeding depends heavily on whether something has disrupted the lung’s capillary barrier; as the smoking data show, it is often the lungs’ exposure to irritants rather than the antibody levels that determines whether hemorrhage occurs.
Early symptoms can be vague: fatigue, malaise, joint aches, or a cough tinged pink with blood. Because these overlap with many common illnesses, the diagnosis is sometimes delayed unless a clinician specifically checks kidney function and asks about hemoptysis (coughing up blood). The disease can progress from first symptoms to dialysis-dependent kidney failure within days, which is why it is treated as an emergency once suspected.
How It Is Diagnosed
Diagnosis rests on finding anti-GBM antibodies either in the blood or in kidney tissue. A blood test using an enzyme-linked immunosorbent assay (ELISA) can detect circulating antibodies with high accuracy and is often the fastest way to confirm suspicion.9Nephrology Dialysis Transplantation. Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes Newer assay formats, such as a chemiluminescence immunoassay, have pushed sensitivity to 100% in validation studies, catching cases that the older ELISA can miss.10PubMed Central. Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
A kidney biopsy provides additional information that blood tests cannot. It shows the characteristic linear immunoglobulin deposition along the basement membrane and reveals how much irreversible scarring has already occurred. The proportion of glomeruli that have formed “crescents,” scar-like inflammatory lesions, is one of the strongest predictors of whether kidney function can be saved. Blood tests, urine analysis, and biopsy findings together guide decisions about how aggressively to treat.
Lung hemorrhage can be detected at the bedside or in the pulmonary function lab. Monitoring the uptake of carbon monoxide during a breathing test can reveal ongoing lung bleeding even before it shows up on imaging, because hemoglobin in the air sacs absorbs carbon monoxide at unusually high rates.11PubMed. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture’s syndrome
Standard Treatment
Treatment needs to accomplish two things fast: remove the antibodies already in circulation and stop the immune system from making more. The standard regimen combines plasma exchange with immunosuppressive drugs.
Plasma exchange (also called plasmapheresis) physically filters the patient’s blood, replacing the antibody-laden plasma with a protein solution. This was first demonstrated in a seminal 1976 study that showed rapid clearance of circulating antibodies, quick resolution of lung hemorrhage, and preservation of kidney function in patients who were not yet on dialysis at presentation.12PubMed. Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome Plasma exchange sessions typically run daily or near-daily for about two weeks, though the duration can vary.13Nephrology Dialysis Transplantation. Anti-glomerular basement membrane disease—treatment standard – Section: Plasma exchange
Alongside plasma exchange, patients receive cyclophosphamide (an immunosuppressive drug) and high-dose corticosteroids to suppress the immune response that is driving antibody production.14PubMed. Plasma exchange in anti-glomerular basement membrane disease The cyclophosphamide course usually lasts about three months. Corticosteroids are tapered gradually. The entire treatment arc is intense but time-limited: unlike many autoimmune conditions, anti-GBM disease tends to be a single episode. Relapses in patients who were only anti-GBM positive (without additional antibody types) are extremely rare.
Prognosis Depends on How Much Kidney Is Left
The single most important factor in long-term kidney survival is how much damage has already occurred by the time treatment begins. A large long-term follow-up study divided patients into three groups based on kidney function at presentation and found starkly different outcomes. Those who arrived with moderately impaired but not yet critically damaged kidneys had outstanding results: 100% patient survival and 95% kidney survival at one year. Those with severe impairment but not yet on dialysis still did well, with about 82% keeping their kidneys at one year. But patients who were already dialysis-dependent at presentation had only an 8% chance of recovering enough kidney function to come off dialysis, and long-term patient survival in this group was just 36%.15PubMed. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression – Section: RESULTS
Biopsy findings reinforce this picture. The percentage of normal glomeruli remaining, the proportion overwhelmed by crescents, and the degree of scarring all influence whether the kidneys can recover.16Advances in Kidney Disease and Health. Anti–Glomerular Basement Membrane Disease: Recent Updates – Section: Disease Prognosis and Predictors of Outcome Patients who had 100% crescents on biopsy and required immediate dialysis uniformly remained dialysis-dependent despite full treatment.17PubMed. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression – Section: RESULTS This is why speed matters: every day of delay in starting plasma exchange and immunosuppression allows more glomeruli to be destroyed beyond repair.
When Anti-GBM Overlaps with ANCA
Roughly 10 to 40% of patients with anti-GBM antibodies also test positive for another type of autoantibody called ANCA, which is associated with a different group of autoimmune conditions affecting small blood vessels.18PubMed. Goodpasture’s disease: a report of ten cases and a review of the literature These “double-positive” patients are a clinically distinct group that does not fit neatly into either diagnostic category.
Double-positive patients tend to be older and to have had symptoms for longer before diagnosis, resembling ANCA-associated vasculitis in their demographics. But their kidney disease and lung hemorrhage tend to be as severe as in pure anti-GBM disease. One important difference is the potential for recovery: even among those who were dialysis-dependent at presentation, double-positive patients had a somewhat greater tendency to come off dialysis after treatment compared with pure anti-GBM patients.19PubMed Central. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients – Section: Abstract
The downside is relapse. Pure anti-GBM disease almost never comes back after a single treated episode. In contrast, about half of surviving double-positive patients experienced disease recurrence over a median follow-up of nearly five years, similar to the relapse rate seen in ANCA-associated vasculitis alone.20PubMed Central. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients – Section: Abstract That means double-positive patients need longer surveillance and may require maintenance immunosuppression, unlike the relatively clean stop-and-watch approach used in anti-GBM-only disease.
Newer Therapies Under Investigation
Standard treatment with plasma exchange and cyclophosphamide works well if started early, but it has clear limitations for patients who arrive late. Two newer approaches have shown promise in the hardest-to-treat cases.
Imlifidase
Imlifidase is an enzyme originally derived from a streptococcal bacterium that cleaves all circulating IgG antibodies within hours of a single infusion. In a phase 2a trial of 15 patients with severe anti-GBM disease, all had undetectable antibody levels just six hours after receiving imlifidase. At six months, two thirds of these patients were free of dialysis, compared with only about 18% in a historical comparison group treated conventionally.21PubMed Central. Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study – Section: Results The speed of antibody removal is the key advantage. Standard plasma exchange takes days to bring antibody levels down; imlifidase does it in hours. Researchers are now studying the autoantibody profile in treated patients to better understand whether new antibodies produced after imlifidase clearance pose any ongoing risk.22Nephrology Dialysis Transplantation. Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment – Section: Abstract
Rituximab
Rituximab, a drug that depletes the immune cells responsible for producing antibodies, has been used in cases that fail standard therapy or relapse. In a review of 22 cases, rituximab led to undetectable or near-undetectable anti-GBM antibody levels in all but one patient, with resolution of symptoms.23PubMed Central. Rituximab for Anti–Glomerular Basement Membrane Disease – Section: Discussion A separate small series of eight patients reported complete remission in seven, with 100% patient survival and 75% kidney survival over a mean follow-up of about two years.24PubMed. Rituximab in anti-GBM disease: A retrospective study of 8 patients More recently, a larger analysis found that even when rituximab was used as a second-line rescue after cyclophosphamide had failed, kidney survival was still 88% among patients who were not dialysis-dependent and 44% among those who were.25Kidney International Reports. Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease – Section: Discussion These numbers are encouraging for a population that has already failed the standard approach, though all the evidence so far comes from case series rather than randomized trials.
Kidney Transplantation After Anti-GBM Disease
For patients whose kidneys are destroyed by the disease, transplantation is an option once the autoimmune attack has fully subsided. The longstanding guideline is to wait until anti-GBM antibodies have been undetectable for at least six to twelve months before transplanting, to minimize the risk of the disease recurring in the new kidney. That caution appears well-founded: in a study of 26 patients who received transplants for end-stage kidney disease caused by anti-GBM disease, only one experienced recurrence.26PubMed Central. Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease – Section: Abstract Long-term graft and patient survival in these transplant recipients were comparable to outcomes in patients transplanted for other common kidney diseases.
The low recurrence rate after transplantation reinforces an unusual feature of anti-GBM disease. Unlike many autoimmune conditions that wax and wane for years, pure anti-GBM disease tends to burn out. The immune system produces the harmful antibodies for a limited period, and once they are cleared and production stops, most patients develop a kind of self-tolerance. Regulatory immune cells have been implicated in this natural shutdown. For patients, the practical meaning is that the fight is intense but usually finite: survive the acute episode with as much kidney function as possible, and the disease is unlikely to return.